BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

760 related articles for article (PubMed ID: 3084648)

  • 21. Effects of systemic recombinant interleukin-2 on natural killer and lymphokine activated killer activity of human tumor infiltrating lymphocytes.
    Anderson TM; Ibayashi Y; Tokuda Y; Colquhoun SD; Holmes EC; Golub SH
    Cancer Res; 1988 Mar; 48(5):1180-3. PubMed ID: 3257716
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bacterial activation of human natural killer cells. Characteristics of the activation process and identification of the effector cell.
    Tarkkanen J; Saksela E; Lanier LL
    J Immunol; 1986 Oct; 137(8):2428-33. PubMed ID: 3093576
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Positively selected Leu-11a (CD16+) cells require the presence of accessory cells or factors for the lysis of herpes simplex virus-infected fibroblasts but not herpes simplex virus-infected Raji.
    Fitzgerald-Bocarsly P; Feldman M; Curl S; Schnell J; Denny T
    J Immunol; 1989 Aug; 143(4):1318-26. PubMed ID: 2526183
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo and ex vivo antitumor activity in patients receiving low-dose subcutaneous recombinant interleukin-2.
    Schomburg A; Menzel T; Körfer A; Heer G; Dallmann I; Kirchner H; Poliwoda H; Atzpodien J
    Nat Immun; 1992; 11(3):133-43. PubMed ID: 1392401
    [TBL] [Abstract][Full Text] [Related]  

  • 25. H-2 antigen expression and sensitivity of BL6 melanoma cells to natural killer cell cytotoxicity.
    Gorelik E; Gunji Y; Herberman RB
    J Immunol; 1988 Mar; 140(6):2096-102. PubMed ID: 3126240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo effects of recombinant IL-2. I. Isolation of circulating Leu-19+ lymphokine-activated killer effector cells from cancer patients receiving recombinant IL-2.
    McMannis JD; Fisher RI; Creekmore SP; Braun DP; Harris JE; Ellis TM
    J Immunol; 1988 Feb; 140(4):1335-40. PubMed ID: 3257776
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characteristics and mechanism of IFN-gamma-induced protection of human tumor cells from lysis by lymphokine-activated killer cells.
    de Fries RU; Golub SH
    J Immunol; 1988 May; 140(10):3686-93. PubMed ID: 3129500
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
    Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protection of cultured human monocytes from lymphokine-activated killer-mediated lysis by IFN-gamma.
    Blanchard DK; Djeu JY
    J Immunol; 1988 Dec; 141(11):4067-73. PubMed ID: 2460557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of natural and recombinant IL 2 on regulation of IFN gamma production and natural killer activity: lack of involvement of the Tac antigen for these immunoregulatory effects.
    Ortaldo JR; Mason AT; Gerard JP; Henderson LE; Farrar W; Hopkins RF; Herberman RB; Rabin H
    J Immunol; 1984 Aug; 133(2):779-83. PubMed ID: 6203980
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lymphokine-activated killer (LAK) cell phenomenon. IV. Lysis by LAK cell clones of fresh human tumor cells from autologous and multiple allogeneic tumors.
    Rayner AA; Grimm EA; Lotze MT; Wilson DJ; Rosenberg SA
    J Natl Cancer Inst; 1985 Jul; 75(1):67-75. PubMed ID: 2989604
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of IL-4 in proliferation and differentiation of human natural killer cells. Study of an IL-4-dependent versus an IL-2-dependent natural killer cell clone.
    Hayakawa K; Salmeron MA; Kornbluth J; Bucana C; Itoh K
    J Immunol; 1991 Apr; 146(7):2453-60. PubMed ID: 1900882
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells.
    Vujanovic NL; Herberman RB; Olszowy MW; Cramer DV; Salup RR; Reynolds CW; Hiserodt JC
    Cancer Res; 1988 Feb; 48(4):884-90. PubMed ID: 3257412
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lymphokine-activated and natural killer cell activity in human intestinal mucosa.
    Hogan PG; Hapel AJ; Doe WF
    J Immunol; 1985 Sep; 135(3):1731-8. PubMed ID: 3926882
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Natural killer and activated killer activities in chronic liver disease and hepatocellular carcinoma: evidence for a decreased lymphokine-induced activity of effector cells.
    Hirofuji H; Kakumu S; Fuji A; Ohtani Y; Murase K; Tahara H
    Clin Exp Immunol; 1987 May; 68(2):348-56. PubMed ID: 2820634
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapid killing of actinomycin D-treated tumor cells by human mononuclear cells. I. Effectors belong to the monocyte-macrophage lineage.
    Colotta F; Peri G; Villa A; Mantovani A
    J Immunol; 1984 Feb; 132(2):936-44. PubMed ID: 6690624
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Killer cell recruitment and renewal capacity of purified cytolytic and noncytolytic human peripheral blood natural killer cell subsets.
    Lebow LT; Jewett A; Bonavida B
    J Immunol; 1993 Jan; 150(1):320-9. PubMed ID: 8417130
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential effects of tyrosine kinase inhibition in CD69 antigen expression and lytic activity induced by rIL-2, rIL-12, and rIFN-alpha in human NK cells.
    Gerosa F; Tommasi M; Benati C; Gandini G; Libonati M; Tridente G; Carra G; Trinchieri G
    Cell Immunol; 1993 Sep; 150(2):382-90. PubMed ID: 8103709
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Generation of lymphokine-activated killer cell activity from human thymocytes.
    Ramsdell FJ; Golub SH
    J Immunol; 1987 Sep; 139(5):1446-53. PubMed ID: 2442246
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term killing of natural killer-resistant target cells by interferon-alpha-, interferon-gamma-, and interleukin-2-activated natural killer cells.
    Sarzotti M; Klimpel GR; Baron S
    Nat Immun Cell Growth Regul; 1989; 8(2):66-75. PubMed ID: 2503715
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.